Novartis/Idenix Request Priority Review For Once-Daily Chronic Hepatitis B Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Telbivudine demonstrates significantly greater viral suppression compared to lamivudine in one-year data.